Nachrichten zur Astellas Pharma Inc. Aktie

Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease

TOKYO, June 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that…

Astellas Pharma Submits Fezolinetant NDA To FDA

TOKYO (dpa-AFX) - Astellas Pharma Inc. said that it has submitted new drug application for fezolinetant to the U.S. Food…

Astellas Submits Fezolinetant New Drug Application to U.S. FDA

Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO, June 23, 2022 /PRNewswire/ -- Astellas…

GlobalStem Cell Therapy Markets Research Report 2022-2031 Featuring Major Players - Anterogen; JCR Pharmaceuticals; Medipost; Osiris Therapeutics; Pharmicell; Astellas Pharma; Cellectis; Celyad

DUBLIN, June 21, 2022 /PRNewswire/ -- The "Stem Cell Therapy Global Market Report 2022: By Type, By Cell, By Application,…

Astellas unit to pay $20.5M upfront to GO Therapeutics in collaboration to discover cancer therapies

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Interstitial Cystitis Drugs Market - 36% of Growth to Originate from North America| Evolving Opportunities with Astellas Pharma Inc. & Bayer AG | 17000+ Technavio Reports

NEW YORK, June 1, 2022 /PRNewswire/ -- The "Interstitial Cystitis Drugs Market by Type (Oral therapy and Intravesical therapy) and…

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

- Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc.…

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO, May 12, 2022 /PRNewswire/ --…

Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting

Astellas investigational nonhormonal treatment meets all primary endpoints, significantly reducing the frequency and severity of vasomotor symptoms associated with menopause…

Astellas Pharma FY21 Core Profit Decreases; Revenue Up 3.7%

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) reported that its fiscal 2021 core operating profit decreased by 2.6% year-on-year…

University Of Tokyo, Astellas Pharma Enter Second Phase Of Collaboration

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced the company and the University of Tokyo have entered the second…

University of Tokyo, Astellas Enter Second Phase of Strategic Partnership for Co-creation of Innovative New Medicines and Medical Solutions

TOKYO, April 25, 2022 /PRNewswire/ -- The University of Tokyo (President: Teruo Fujii, Ph.D.) and Astellas Pharma Inc. (TSE: 4503,…

USD 30.23 billion growth expected in Non-Small Cell Lung Cancer Drugs Market | Evolving Opportunities with AbbVie Inc. and Amgen Inc. | Technavio

NEW YORK, April 20, 2022 /PRNewswire/ -- The global non-small cell lung cancer drugs market size is expected to increase…

European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer

- Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and…

Globale Pharmaunternehmen unterstützen Turn Biotechnologies bei der Weiterentwicklung seines Zellverjüngungsprogramms

Turn Biotechnologies, Inc.: Mountain View, Kalifornien (ots/PRNewswire) - Daewoong Pharmaceutical und HanAll Biopharma beteiligen sich gemeinsam mit Astellas Venture Management…

CYTOO-Partner Astellas Gene Therapies hat die Ergebnisse einer AGT/CYTOO-Kooperation zur Auswahl klinischer Kandidaten für die Behandlung von DMD auf dem zweiten Gentherapie-Gipfel für Muskelkrankheiten vorgestellt

GRENOBLE, Frankreich--(BUSINESS WIRE)--CYTOO und Astellas Gene Therapies (AGT) sind im Jahr 2020 eine Forschungskooperation eingegangen, um den klinischen AAV-Gentherapie-Kandidaten von…

Astellas hot flashes treatment fezolinetant fails in late-stage study in Asia

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas: Phase 3 Study Of Fezolinetant On VMS Associated With Menopause Did Not Show Efficacy

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that 12-week data from phase 3 MOONLIGHT 1 study of fezolinetant…

Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia

Astellas MOONLIGHT 1TM clinical trial evaluating investigational fezolinetant 30 mg administered once daily TOKYO, March 14, 2022 /PRNewswire/ -- Astellas…

Central Nervous System (CNS) Stimulant Drugs Market to grow at a CAGR of 5.74 by 2026 | Rise in CNS Disorders to Boost Growth | 17000+ Technavio Reports

NEW YORK, March 14, 2022 /PRNewswire/ -- The central nervous system (CNS) stimulant drugs market is fragmented and the vendors…

Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Small Molecules for Oncology Target

NEW YORK, March 10, 2022 /PRNewswire/ -- Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to…

Astellas Worth A Look On Revenue Re-Acceleration Potential

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause

TOKYO, March 7, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…

Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

TOKYO and BOTHELL, Wash., Feb. 14, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas")…

Astellas Pharma Inc. 2021 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astellas Pharma Announces Positive Data From Study Of AT845 In Adults With Late-Onset Pompe Disease

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced positive interim safety data from FORTIS Study. The Phase I/II clinical…

Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease

TOKYO, Feb. 7, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced…

Astellas Pharma reports 9M results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company Initial…

Overactive Bladder Market Spotlight Report 2021: Astellas has the Highest Number of Completed Clinical Trials with 176 Trials

DUBLIN, Jan. 28, 2022 /PRNewswire/ -- The "Market Spotlight: Overactive Bladder" report has been added to ResearchAndMarkets.coms offering. Overactive bladder…

Biotech - Basilea erzielt mit Cresemba-Umsätzen Meilensteinzahlung von 15 Mio Franken

Das Biopharmaunternehmen Basilea hat vom US-Partners Astellas Pharma eine Meilensteinzahlung in Höhe von 15 Millionen Franken erhalten....…

Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR...…

Starke Cresemba® (Isavuconazol) Umsätze von Astellas in den USA lösen CHF 15 Mio. Meilensteinzahlung an Basilea aus

Ad hoc-Mitteilung gemäss Art. 53 KR...…

Leuprolide Acetate Market to Record 10.42% Y-O-Y Growth Rate in 2022 |Evolving Opportunities with AbbVie Inc. & Astellas Pharma Inc. | 17000+ Technavio Reports

NEW YORK, Jan. 3, 2022 /PRNewswire/ -- Technavios latest research report on the Leuprolide Acetate Market offers a comprehensive analysis…

Worldwide TIGIT Inhibitor Industry - Featuring Acrus Biosciences, Astellas Pharma and AstraZeneca Among Others

DUBLIN, Dec. 20, 2021 /PRNewswire/ -- The "Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022" report has been…

Astellas, Seagen Announce Positive CHMP Opinion For PADCEV

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) said the CHMP of the European Medicines Agency…

Astellas Pharma, Seagen Get CHMP Positive Opinion for Padcev

Astellas Pharma, Seagen Get CHMP Positive Opinion for Padcev...…

Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

TOKYO and BOTHELL, Wash., Dec. 17, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas")…

Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact

Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY). read more...…

Astellas, Dyno Therapeutics To Develop AAV Gene Therapy Vectors For Skeletal And Cardiac Muscle

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) and Dyno Therapeutics Inc. said that they have reach an agreement to…

Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle

TOKYO and CAMBRIDGE, Mass, Dec. 1, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,…

Interstitial Cystitis Drugs Market to Grow by USD 283.95 mn from 2020 to 2025| Astellas Pharma Inc. and Bayer AG among Key Vendors | Technavio

NEW YORK, Nov. 17, 2021 /PRNewswire/ -- The interstitial cystitis drugs market is expected to grow by USD 283.95 mn…